US EditionBipartisan senators offer new bill aimed at lowering drug prices
- Senators Josh Hawley of Missouri and Peter Welch of Vermont proposed a bill aimed at reducing prescription drug costs for American consumers.
- The bill addresses decades of policies that have allowed pharmaceutical companies to charge Americans higher prices than in other developed countries.
- It would prohibit selling drugs in the U.S. Above the international average price and impose penalties ten times the price difference per unit sold.
- Senator Hawley remarked that for an extended period, U.S. Consumers have effectively borne the financial burden of prescription drugs for other countries, while facing excessively high prices for their own medications.
- The legislation aims to reduce medication costs for millions and offers a framework for Congress and the administration to achieve affordable drug prices.
7 Articles
7 Articles
Bipartisan senators offer new bill aimed at lowering drug prices
A bipartisan pair of senators introduced legislation to lower prescription drug prices by prohibiting pharmaceutical companies from selling drugs in the U.S. at higher prices than the international average. The bill from Sens. Josh Hawley (R-Mo.) and Peter Welch (D-Vt.) is a riff on the “most favored nation” policy President Trump pushed in his first…
Pharmacists demand urgent control over rising medicine prices
A representational image of medicines. — Pexels/FileAlarmed by the continuous rise in medicine prices across Pakistan, the Pakistan Pharmacist Association’s Sindh chapter on Sunday demanded immediate policy action from the government and the Drug Regulatory Authority of Pakistan to...
Senators Unveil Bipartisan Bill to Lower Drug Costs
Sens. Josh Hawley (R-MO) and Peter Welch (D-VT) "are teaming up on bipartisan legislation aimed at lowering drug costs by barring drug companies in the U.S. from charging higher prices than the international average," Politico reports."While their bill is different from what the Trump administra
Coverage Details
Bias Distribution
- 50% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
